Boehringer walks away from Zealand's lead glucagon/GLP-1 receptor agonist
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim and Zealand Pharma have had a difference of opinion over ZP2929, the lead compound in their development program for novel dual-acting glucagon/GLP-1 receptor agonists for diabetes and potentially obesity.